Opinion
Video
Advancing Friedreich Ataxia Treatment With FDA-Approved Therapies
Author(s):
An expert discusses how omaveloxolone is a nuclear factor erythroid 2-related factor 2 (Nrf2) activator that addresses oxidative stress and mitochondrial dysfunction in Friedreich ataxia. It works by binding to Keap1, which releases Nrf2 to enter the nucleus and upregulate antioxidant genes. Clinical trials showed modest improvements in neurological function, as measured by modified Friedreich Ataxia Rating Scale scores. Adverse effects include headache, nausea, and elevated liver enzymes. Omaveloxolone has been integrated into clinical practice as part of multidisciplinary care, requiring regular monitoring and coordination with physical therapy, cardiology, and other specialties.
Video content above is prompted by the following:
- What is the mechanism of action of omaveloxolone, which is the first and only FDA-approved drug for the treatment of Friedreich ataxia for patients 16 years of age and older?
- Please discuss the efficacy, safety, and quality-of-life data for omaveloxolone.
- How have you integrated omaveloxolone into your clinical practice and multidisciplinary treatment approach?
FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
